Association of Osteonecrosis of the Jaw With Zoledronic Acid Treatment for Bone Metastases in Patients With Cancer

This cohort study (n=3,491) found the cumulative incidence of osteonecrosis of the jaw was 0.8% at year 1, 2.0% at year 2, and 2.8% at year 3, with highest rates in those with multiple myeloma. More frequent dosing (interval <5 weeks) was associated with increased risk.

JAMA Oncology